Two peptides commonly studied together for their interaction with growth hormone pathways. Here is what the research says and what legal access looks like in Australia.
This article is for general educational purposes only and does not constitute medical advice. CJC-1295 and Ipamorelin are prescription-only medicines in Australia. Access requires assessment and prescription from an AHPRA-registered medical practitioner. Always consult a qualified doctor before making any decisions about your health.
CJC-1295 and Ipamorelin are two peptide compounds that are frequently discussed together in research and clinical contexts because of the complementary way they interact with growth hormone pathways. Understanding what each compound is individually, and why they are often studied and prescribed together, helps make sense of why they appear so frequently in discussions about peptide therapy in Australia.
This guide covers what each compound is, how researchers have studied their mechanisms, the current state of the evidence, and what proper legal access looks like in Australia.
A synthetic analogue of growth hormone releasing hormone. Studied for its interaction with GHRH receptors and influence on growth hormone signalling.
A selective growth hormone secretagogue. Studied for its ability to stimulate growth hormone release through a different receptor pathway to CJC-1295.
Both are Schedule 4 prescription-only medicines in Australia. Require a valid prescription from an AHPRA-registered doctor.
CJC-1295 is a synthetic peptide analogue of growth hormone releasing hormone, commonly referred to as GHRH. GHRH is a hormone naturally produced by the hypothalamus that signals the pituitary gland to release growth hormone. CJC-1295 is designed to interact with the same GHRH receptors, mimicking and extending this signalling process.
A key characteristic of CJC-1295 that distinguishes it from earlier GHRH analogues is its extended half-life. Earlier GHRH analogues were rapidly broken down in the body, limiting their research utility. CJC-1295 was designed to resist this degradation, allowing it to remain active for longer and making it more practical as a research compound and in clinical settings.
CJC-1295 is available in two forms. One version includes what is referred to as Drug Affinity Complex, or DAC, which binds to albumin in the blood and further extends the compound's active duration significantly. The other version without DAC has a shorter active window. The prescribing doctor determines which form is appropriate for an individual based on their specific circumstances and protocol.
Ipamorelin is a selective growth hormone secretagogue, meaning it stimulates the release of growth hormone from the pituitary gland. Unlike CJC-1295, which works through the GHRH receptor pathway, Ipamorelin works through a different receptor called the ghrelin receptor, also known as the growth hormone secretagogue receptor.
What has made Ipamorelin of particular research interest is its selectivity. Earlier growth hormone secretagogues were associated with stimulating the release of other hormones alongside growth hormone, including cortisol and prolactin. Research into Ipamorelin has examined whether it can stimulate growth hormone release with greater selectivity and fewer effects on these other hormonal pathways, though individual responses vary and a doctor assessment remains the appropriate way to evaluate whether it is suitable for any individual.
The rationale for combining CJC-1295 and Ipamorelin relates to their complementary mechanisms. CJC-1295 works through the GHRH receptor to signal the pituitary to produce growth hormone. Ipamorelin works through the ghrelin receptor to independently stimulate growth hormone release. Because they act on different receptors through different pathways, research has examined whether using them together produces a more pronounced effect on growth hormone signalling than either compound alone.
Important context: The combination of CJC-1295 and Ipamorelin is one of the more commonly discussed pairings in peptide research and clinical contexts. However, as with all compounds in this space, the appropriateness of any protocol, including whether a combination approach is suitable, is something that is determined by a prescribing doctor based on an individual's health history and goals, not something that should be self-directed based on online information.
Research into CJC-1295 and Ipamorelin individually and in combination has examined their interaction with growth hormone pathways and the downstream effects that growth hormone influences in the body. These include areas related to body composition, recovery processes, sleep quality and metabolic function, all of which are influenced by growth hormone signalling.
It is important to be honest about the evidence base. Much of the research into these compounds, particularly regarding their use in combination, has been conducted in animal models or small clinical studies. The evidence for specific outcomes in diverse human populations is less developed than the volume of online discussion might suggest. This is why a proper medical assessment is the correct starting point rather than drawing conclusions from research summaries found online.
Because CJC-1295 influences growth hormone and IGF-1 pathways, protocols involving this compound typically require blood testing. At UHD BioHealth, clients on CJC-1295 protocols are required to provide updated blood test results before continuing to a subsequent protocol round. This is not a formality. It is a genuine clinical safeguard that allows the prescribing doctor to monitor how the individual is responding and make informed decisions about whether continuation is appropriate.
This monitoring requirement is one of the things that distinguishes properly supervised peptide therapy from unregulated self-directed use. A doctor who can review your blood work before approving a continuation is providing a level of oversight that unregulated sources cannot.
Yes, under the same framework that applies to all therapeutic peptides in Australia. Both compounds are Schedule 4 prescription-only medicines. They are legal to access when prescribed by an AHPRA-registered medical practitioner following a clinical assessment, and dispensed through a licensed compounding pharmacy.
They cannot be legally purchased without a prescription, imported for personal use without proper authorisation, or sourced from unregulated online channels. Products available outside this framework have not been evaluated for safety, purity or potency.
The process starts with a free eligibility assessment. There is no cost to find out whether a protocol involving CJC-1295 and Ipamorelin might be appropriate for your situation. A prescribing doctor reviews your information and, if clinically appropriate, prepares a personalised protocol for your consideration.
Because CJC-1295 protocols require blood monitoring, clients are asked to provide blood test results before proceeding to subsequent rounds. If you would like to continue after your initial protocol, the process of arranging the required blood tests is straightforward and the doctor can review and approve quickly once results are available.
Start with a free assessment. A doctor reviews your history and goals and builds a protocol around your specific situation if one is appropriate. No cost until you choose to proceed.